CRISPR-Cas9 for TTR Amyloidosis; Osmotic Demyelination Syndrome Dr. Alberto Espay talks with Prof. Julian Gillmore about CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. Dr. Pearce Korb discusses the long-term outcomes of osmotic demyelination syndrome in an updated cohort with Dr. Whitney Fitts. October 12, 2021 Issue Neurology, Journal, Podcast Listen22:12 Disclosures View Recent Podcasts
